Ivermectin is a medicine for parasitic infections being researched for cancer. Human reports do not establish improved tumor control, survival, or quality of life. Short-course safety does not establish safety of sustained cancer use. Severe harm to the nervous system, liver injury, allergic reactions, and drug interactions are documented; replacing effective treatment adds risk. No validated cancer dose, duration, or monitoring target has emerged. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood pressure | Baseline comparison | Establish safety context |
| Alanine and aspartate aminotransferases | No established ivermectin-specific optimal target; baseline and laboratory upper limits | Detect liver injury |
| Bilirubin | No established functional target; baseline and local reference interval | Detect liver dysfunction |
| Albumin | No established anticancer target; baseline and nutritional context | Interpret binding and illness |
| Complete blood count | No established ivermectin-specific optimal range; baseline, symptoms, regimen thresholds | Track blood-cell production (hemoglobin, neutrophils, platelets) |
| Creatinine and estimated kidney filtration | No established functional target for ivermectin; baseline and trend | Assess organ function |
| International normalized ratio | Individual anticoagulation target; commonly 2.0–3.0 for relevant warfarin indications | Detect excessive anticoagulation |
| Pregnancy test | Negative when required by protocol | Prevent fetal exposure |
| Tumor imaging and disease-specific markers | No established ivermectin target; same lesions and appropriate baseline markers | Measure cancer course |
Cadence: Baseline; pragmatic reassessment at 1–2 weeks, before each three-week cycle, and immediately for new symptoms; not an evidence-validated ivermectin schedule. Imaging and pregnancy retesting follow the study; warfarin checks follow the anticoagulation service.